The closing price of Laboratory Corp. Of America Holdings (NYSE: LH) was $209.01 for the day, down -3.12% from the previous closing price of $215.75. In other words, the price has decreased by -$6.74 from its previous closing price. On the day, 1582556 shares were traded.
Ratios:
Our analysis of LH’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 32.75 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 20.11. For the most recent quarter (mrq), Quick Ratio is recorded 1.02 and its Current Ratio is at 1.17. In the meantime, Its Debt-to-Equity ratio is 0.76 whereas as Long-Term Debt/Eq ratio is at 0.61.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Leerink Partners on February 26, 2024, initiated with a Outperform rating and assigned the stock a target price of $260.
On February 09, 2024, Evercore ISI started tracking the stock assigning a In-line rating and target price of $240.
On January 03, 2024, Barclays started tracking the stock assigning a Equal Weight rating and target price of $222.Barclays initiated its Equal Weight rating on January 03, 2024, with a $222 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 07 ’24 when Schroeder Mark S sold 5,048 shares for $218.45 per share. The transaction valued at 1,102,736 led to the insider holds 5,036 shares of the business.
Summy Amy B. sold 227 shares of LH for $49,588 on Mar 07 ’24. The EVP, Chief Marketing Officer now owns 3,859 shares after completing the transaction at $218.45 per share. On Feb 21 ’24, another insider, EISENBERG GLENN A, who serves as the Chief Financial Officer, EVP of the company, sold 34,504 shares for $215.97 each. As a result, the insider received 7,451,866 and left with 23,595 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LH now has a Market Capitalization of 17.58B and an Enterprise Value of 23.00B. As of this moment, Laboratory’s Price-to-Earnings (P/E) ratio for their current fiscal year is 44.92, and their Forward P/E ratio for the next fiscal year is 12.98. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.82. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.36 while its Price-to-Book (P/B) ratio in mrq is 2.23. Its current Enterprise Value per Revenue stands at 1.89 whereas that against EBITDA is 17.09.
Stock Price History:
Over the past 52 weeks, LH has reached a high of $234.09, while it has fallen to a 52-week low of $179.58. The 50-Day Moving Average of the stock is 221.57, while the 200-Day Moving Average is calculated to be 211.60.
Shares Statistics:
LH traded an average of 725.23K shares per day over the past three months and 726.52k shares per day over the past ten days. A total of 83.90M shares are outstanding, with a floating share count of 83.84M. Insiders hold about 0.30% of the company’s shares, while institutions hold 97.78% stake in the company. Shares short for LH as of Feb 29, 2024 were 2.13M with a Short Ratio of 2.94, compared to 2.5M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 2.53% and a Short% of Float of 3.44%.
Dividends & Splits
With its trailing 12-month dividend rate of 2.88, LH has a forward annual dividend rate of 2.88. Against a Trailing Annual Dividend Yield of 1.33%, it implies a Forward Annual Dividend Yield of 1.38%. The current Payout Ratio is 60.36% for LH, which recently paid a dividend on Mar 13, 2024 with an ex-dividend date of Feb 26, 2024. Stock splits for the company last occurred on May 13, 2002 when the company split stock in a 2:1 ratio.
Earnings Estimates
The firm’s stock currently is rated by 14 analysts. On average, analysts expect EPS of $3.51 for the current quarter, with a high estimate of $3.67 and a low estimate of $3.3, while EPS last year was $3.46. The consensus estimate for the next quarter is $3.81, with high estimates of $3.97 and low estimates of $3.62.
Analysts are recommending an EPS of between $14.97 and $14.45 for the fiscal current year, implying an average EPS of $14.82. EPS for the following year is $16.05, with 16 analysts recommending between $16.67 and $15.38.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 12 analysts. It ranges from a high estimate of $3.16B to a low estimate of $3.08B. As of the current estimate, Laboratory Corp. Of America Holdings’s year-ago sales were $3.78B, an estimated decrease of -17.30% from the year-ago figure. For the next quarter, 12 analysts are estimating revenue of $3.2B, an increase of 5.30% over than the figure of -$17.30% in the same quarter last year. There is a high estimate of $3.25B for the next quarter, whereas the lowest estimate is $3.18B.
A total of 16 analysts have provided revenue estimates for LH’s current fiscal year. The highest revenue estimate was $12.83B, while the lowest revenue estimate was $12.63B, resulting in an average revenue estimate of $12.75B. In the same quarter a year ago, actual revenue was $12.16B, up 4.90% from the average estimate. Based on 16 analysts’ estimates, the company’s revenue will be $13.31B in the next fiscal year. The high estimate is $13.55B and the low estimate is $12.9B. The average revenue growth estimate for next year is up 4.30% from the average revenue estimate for this year.
